Since sinomenine can effectively reduce the TNF levels in activated microglia and microphages [21, 23], it is possible that sinomenine's analgesic mechanism is partially mediated through downregulating the activity of TNF, albeit merely deplete TNF alone cannot abolish neuropathic pain, as has already been demonstrated by the failure of the TNF antibody in clinical trials for sciatica [45]. The gene discussed is TNF; the disease is Sciatica.